

NEUROSCIENTIFIC ENHANCES MANAGEMENT TEAM WITH KEY APPOINTMENTS

HIGHLIGHTS

- **Dougal Thring will be promoted from VP of Clinical Development to Chief Operating Officer**
- **Simon Scott has been appointed Director of Clinical Development**
- **The Company is in the final stages of preparations for submission of its safety data package for approval to commence a first-in-human clinical study**

NeuroScientific Biopharmaceuticals Ltd (ASX: **NSB**) (“**NeuroScientific**” or “**the company**”) is pleased to announce the appointment of Dougal Thring as Chief Operating Officer and Simon Scott as Director of Clinical Development, adding significant depth to its clinical leadership team prior to commencing first-in-human clinical studies for lead drug candidate EmtinB™.

Dougal was previously appointed as Vice President of Clinical Development at NeuroScientific in March 2021 and will move into the new position of Chief Operating Officer, working closely with the Executive Management team in overseeing all aspects of nonclinical and clinical research and development activities.

Simon brings more than 15 years’ of clinical research experience with a focus in the past 12 years in early phase clinical research, from clinic based roles at Hammersmith Medicines Research in London to senior management roles with Linear Clinical Research in Perth. Most recently, Simon has held positions including Project Operations Manager, overseeing clinical operations, and Head of Business Development, overseeing front end services at Linear, including BD, start-up and recruitment teams, and thus involved in feasibility, scheduling, provision of protocol and wider document advice for all early phase projects through the company. Simon’s involvement in the early phase, senior management and executive leadership teams has seen him involved in setting and implementing strategy for the sustainable growth of Linear. This, along with his education background in pharmaceutical development and regulation, will provide NeuroScientific a diverse and invaluable set of skills to push EmtinB™ through clinical development.

NeuroScientific’s Managing Director and Chief Executive Officer Matt Liddelow commented: *“As we rapidly approach the commencement of first-in-human clinical studies, which signals a major milestone achievement in the Company’s history, these key appointments reflect the strategic changes necessary to position NeuroScientific for future success as a clinical stage company. Dougal has been an invaluable addition to the team since joining the Company last year and the appointment of Simon adds considerable depth to the clinical operations team. With this management structure in place I look forward to executing on our clinical strategy during CY 2022.”*

With a number of key activities completed, NeuroScientific will provide additional information in regard to its clinical development strategy in a separate announcement in the coming days.

This announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+ 61 8 6382 1805

Lucas Robinson
Investor Relations
Corporate Storytime
lucas@corporatetorytime.com
+ 61 408 228 889

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit www.neuroscientific.com

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.